Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 Vaccine and Pembrolizumab in PD-L1+ HNSCC
NCT05075122Phase 2Unknown
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of UV1 in head and neck squamous cell carcinoma (HNSCC), sponsored by Martin Luther University Halle-Wittenberg. Status: unknown.
02
Drugs
UV1
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05075122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075122.